Skip to search formSkip to main contentSkip to account menu

BMS 599626

Known as: BMS-599626, BMS599626, AC480 
An orally bioavailable pan-HER tyrosine kinase inhibitor with potential antineoplastic activity. BMS-599626 inhibits human epidermal growth factor… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Pharmacologic Substance
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED).
2070 Background: AC480 is a novel oral tyrosine kinase inhibitor of the human epidermal growth factor receptor family, especially… 
2009
2009
Abstract #5651: Intermittent pan-HER inhibition with AC480 in combination with paclitaxel leads to robust synergistic reduction of tumor size in a preclinical model
AC480 is a potent small molecule pan-HER inhibitor currently in Phase 2 of clinical development. Although continuous… 
2008
2008
Détection d'une protéine her-2-neu de cellules cancéreuses en circulation non isolées et traitement
L'invention concerne l'expression d'une proteine Her-2/neu sur des cellules cancereuses en circulation dans un echantillon de… 
2007
2007
A pan Her inhibitor, BMS-599626, augments radiosensitivity of HN5 cells by increasing radiation-induced apoptosis and inhibiting DNA repair.
B247 Purpose: BMS-599626 is a small molecule kinase inhibitor that primarily inhibits Her1 and Her2. Thus, it has potential to be… 
2005
2005
Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors
3152 Background: BMS-599626 is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50=22, 32 and 190… 
2005
2005
Phase I pharmacokinetic profile and early clinical evaluation of the PAN-HER inhibitor BMS-599626
3109 Background: BMS-599626 is an orally bioavailable inhibitor of HER1 (EGFR), HER2 (ErbB2) and to a lesser extent HER4. Methods… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)